ESMO 2019 | MOUNTAINEER results: trastuzumab and tucatinib for HER2+ mCRC
John Strickler, MD, Duke Cancer Center, Durham, NC, discusses the initial results of the MOUNTAINEER trial (NCT03043313). This Phase II trial studies how the HER2 inhibitor tucatinib works in combination with trastuzumab in treating patients with HER2-positive metastatic colorectal cancer (mCRC). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
Get great new content delivered to your inboxSign up